$17.28
0.92% today
Nasdaq, Dec 04, 08:53 pm CET
ISIN
US81750R1023
Symbol
MCRB

Seres Therapeutics Inc Stock price

$17.44
+2.20 14.44% 1M
+10.44 149.14% 6M
+0.82 4.93% YTD
-0.10 0.55% 1Y
-113.16 86.65% 3Y
-487.96 96.55% 5Y
-665.96 97.45% 10Y
-1,010.56 98.30% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.74 4.43%
ISIN
US81750R1023
Symbol
MCRB
Industry

Key metrics

Basic
Market capitalization
$157.8m
Enterprise Value
$110.1m
Net debt
positive
Cash
$47.6m
Shares outstanding
8.8m
Valuation (TTM | estimate)
P/E
28.6 | 177.2
P/S
450.8 | -
EV/Sales
314.7 | -
EV/FCF
negative
P/B
3.6
Financial Health
Equity Ratio
9.9%
Return on Equity
1.0%
ROCE
-85.5%
ROIC
-112.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$350.0k | $0.0
EBITDA
$-99.2m | $-81.6m
EBIT
$-103.4m | $-102.4m
Net Income
$5.4m | $860.0k
Free Cash Flow
$-23.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
25.3% | 27.5%
EBIT
25.5% | 13.2%
Net Income
121.2% | 514.3%
Free Cash Flow
85.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-28,252.1% | -
EBIT
-29,467.0%
Net
1,536.8% | -
Free Cash Flow
-6,657.3%
More
EPS
$0.6
FCF per Share
$-2.7
Short interest
16.3%
Employees
103
Rev per Employee
$0.0
Show more

Is Seres Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Seres Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Seres Therapeutics Inc forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Seres Therapeutics Inc forecast:

Buy
70%
Hold
30%

Financial data from Seres Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.35 0.35
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 44 44
24% 24%
12,594%
- Research and Development Expense 50 50
34% 34%
14,349%
-99 -99
25% 25%
-28,334%
- Depreciation and Amortization 4.26 4.26
29% 29%
1,217%
EBIT (Operating Income) EBIT -103 -103
25% 25%
-29,551%
Net Profit 5.39 5.39
121% 121%
1,540%

In millions USD.

Don't miss a Thing! We will send you all news about Seres Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seres Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m.
Neutral
Seeking Alpha
29 days ago
Seres Therapeutics, Inc. ( MCRB ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Carlo Tanzi Marella Thorell - Co-CEO, Co-President & CFO Matthew Henn - Executive VP & Chief Scientific Officer Dennis M. Walling - Senior VP of Clinical Development & Head of Clinical Research Teresa Young - Executive VP and Chief Commercial & Strategy Officer Conference Call Participants ...
Neutral
GlobeNewsWire
29 days ago
Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results an...
More Seres Therapeutics Inc News

Company Profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Eric Shaff
Employees 103
Founded 2010
Website www.serestherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today